This past quarter has been, without a doubt, the busiest and most transformative three months of this year— perhaps even of the entire history of the psychedelic industry.
Of all the major developments, the release of the MAPP2 phase III clinical trial results was the biggest. The founder and president of MAPS is like the father of the modern psychedelic industry. Most companies in this space have only been around for about 3-5 years. However, Rick Doblin started MAPS 38 years ago.
Subscribe to a PRO account below for complete access to the report.
You must have PRO to access this content.